Lyra Therapeutics, Inc. (LYRA) is a clinical-stage biopharmaceutical company focused on developing therapeutics for ear, nose, and throat (ENT) conditions. Its lead product candidate, LYR-210, is being evaluated in Phase 3 clinical trials for chronic rhinosinusitis. The company is evaluating strategic transactions to maximize shareholder value and has disclosed going concern uncertainties and potential Nasdaq delisting.
Q2 FY2026 — expected 2026-09-16
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-03-31 | 2025-12-31 | 0001327273-26-000003 | EDGAR | 65K words |
| 2025-03-13 | 2024-12-31 | 0000950170-25-038751 | EDGAR | 111K words |
| 2024-03-22 | 2023-12-31 | 0000950170-24-035047 | EDGAR | 107K words |
| 2023-03-29 | 2022-12-31 | 0000950170-23-010632 | EDGAR | 102K words |
| 2022-03-09 | 2021-12-31 | 0001564590-22-009187 | EDGAR | 105K words |
| 2021-03-09 | 2020-12-31 | 0001564590-21-011767 | EDGAR | 99K words |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2025-11-12 | 2025-09-30 | 0001193125-25-277564 | EDGAR | 70K words |
| 2025-08-12 | 2025-06-30 | 0000950170-25-107367 | EDGAR | 70K words |
| 2025-05-06 | 2025-03-31 | 0000950170-25-064495 | EDGAR | 65K words |
| 2024-11-12 | 2024-09-30 | 0000950170-24-125494 | EDGAR | 66K words |
| 2024-08-14 | 2024-06-30 | 0000950170-24-097042 | EDGAR | 66K words |
| 2024-04-30 | 2024-03-31 | 0000950170-24-050535 | EDGAR | 62K words |
| 2023-11-07 | 2023-09-30 | 0000950170-23-060298 | EDGAR | 68K words |
| 2023-08-08 | 2023-06-30 | 0000950170-23-039830 | EDGAR | 66K words |
| 2023-05-12 | 2023-03-31 | 0000950170-23-021497 | EDGAR | 62K words |
| 2022-11-08 | 2022-09-30 | 0000950170-22-023266 | EDGAR | 67K words |
| 2022-08-09 | 2022-06-30 | 0001564590-22-028609 | EDGAR | 65K words |
| 2022-05-10 | 2022-03-31 | 0001564590-22-019102 | EDGAR | 67K words |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-03-16 | 0001193125-26-108439 | EDGAR | 1K words |
| 2026-02-27 | 0001193125-26-083251 | EDGAR | 1K words |
| 2026-02-06 | 0001193125-26-041191 | EDGAR | 1K words |
| 2026-01-12 | 0001193125-26-009772 | EDGAR | 1K words |
| 2025-11-12 | 0001193125-25-277515 | EDGAR | 3K words |
| 2025-09-04 | 0001193125-25-195384 | EDGAR | 3K words |
| 2025-08-22 | 0001193125-25-186437 | EDGAR | 1K words |
| 2025-08-12 | 0000950170-25-107339 | EDGAR | 3K words |
| 2025-08-01 | 0001193125-25-171647 | EDGAR | 1K words |
| 2025-06-27 | 0001193125-25-150301 | EDGAR | 1K words |
110 total filings indexed. 82 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001327273 |
| Ticker | LYRA |
| Exchange | OTC |
| SIC | 3841: Surgical & Medical Instruments & Apparatus |
| Incorporated | DE |
This is a static snapshot. For live, structured JSON with cryptographic provenance chain:
MCP (recommended for AI): claude mcp add origin --transport http https://origin.rootz.global/mcp
Try it — paste this into your AI:
Works in ChatGPT, Claude, Gemini, or any AI. Free, structured, cryptographically signed — ~500 tokens vs 130,000 scraping an IR site.
claude mcp add origin --transport http https://origin.rootz.global/mcpGET https://origin.rootz.global/api/company/LYRA (~200 tokens, structured JSON with cryptographic provenance)